ONE MAN CAN AND WILL FIND A WAY, WHY NOT BE THAT MAN...
Date:January 23, 2015

TW001 Oral Edaravone – ADORE

 

TW001 was tested in both single and multiple dose Phase 1 studies in healthy volunteers and in ALS patients. In the two Phase 1 clinical studies TW001 was shown to be safe and well tolerated and adequate exposure levels with the oral formulation were detected. Based on these trial, we are now aiming to start a pivotal Phase 2/3 study (ADORE – ALS Deceleration study with Oral Edaravone) as soon as possible.